Latest Medical Devices News
Dorsavi Commences Energy Efficiency Study for Next-Gen RRAM AI Hardware
CONNEQT Lands Blueprint Deal After Record $1.3M Revenue Quarter
Optiscan’s InForm Hits 84 Real-World Cases Advancing Path to FDA Clearance
EBR Systems Clears FDA Cybersecurity Review With No Recall Required
OncoSil Clears Key Regulatory Hurdle Toward Australian Production of Cancer Device
Osteopore Enters Thailand’s $60-80M Bone Repair Market via Auriga Partnership
Echo IQ’s Heart Failure Device Hits FDA Setback; $105M Cash Enables Path Forward
Medical Devices ETF Chart
Medical Devices Analysis
Why ResMed Fell 7% on a Quarter That Didn’t Disappoint
ResMed’s FY26 Beat: Why a Strong Result Sent Shares Down 7%
UBS Backs 3 ASX Healthcare Stocks With Up to 100% Upside
ResMed’s 51% Valuation Discount: Bargain or Fair Re-Rating?
Why ASX Healthcare Fell 16 Points Behind the Market in 5 Years
ResMed Shares Down 19.8%: Valuation Trap or Mispriced Opportunity?
Cochlear at AU$97: Quality Business or Permanent Impairment?
Cochlear Falls 63%: Generational Discount or Falling Knife?
Medical Devices Guides & Education
Why the Company Behind Australia’s Green Whistle Trades on ASX
Why a US$740M AI Hearing Raise Reprices ASX Tech Stocks
How ASX Medtech Stocks Win in the World’s Most Cautious Market
What an 86% Untreated Market Means for ASX Health Stocks
3 ASX Blue Chips Built for Long-Term Compounding
How to Use the Price-to-Sales Ratio Without Getting It Wrong
Discover More in the Medical Technology Hub
Go to Hub
Synertec Lands Design Lead Role on ANSTO’s $45.5M Nuclear Medicine Facility
Proteomics International Launches First Tests via Healius 1,900-Site Network
Simble Solutions Clears Second NanoSensor Milestone With UV Detection Confirmed
Radiopharm’s RAD101 Achieves 93% Concordance in Brain Metastases Phase 2b
Dorsavi Commences Energy Efficiency Study for Next-Gen RRAM AI Hardware
CONNEQT Lands Blueprint Deal After Record $1.3M Revenue Quarter
Optiscan’s InForm Hits 84 Real-World Cases Advancing Path to FDA Clearance
EBR Systems Clears FDA Cybersecurity Review With No Recall Required
Featured ASX Medical Devices Announcements
Latest ASX Medical Devices Videos
Medical Equipment Stocks: Industry Trends, Earnings and Investment Analysis
Medical equipment stocks span surgical systems, diagnostic imaging hardware, patient monitoring, and reusable procedural instruments, each with distinct revenue models and competitive barriers. The sector is characterised by long product lifecycles, regulatory moats, and deep hospital relationships that create durable earnings for established players. ASX-listed medical equipment companies have increasingly pursued international expansion to access larger addressable markets. StockWire X tracks earnings results, new product approvals, tender wins, and M&A activity across medical equipment stocks. Capital expenditure cycles in the hospital sector and healthcare funding decisions are key macro drivers our analysis monitors.
Frequently Asked Questions
What are the top 10 medical stocks on the ASX?
The ASX has a comprehensive medical sector spanning pharmaceuticals, medical devices, diagnostics, and health services. Top ASX medical stocks by market cap include globally significant businesses alongside a deep cohort of emerging companies. StockWire X covers ASX medical equipment stocks and the broader healthcare sector with analysis of earnings, clinical milestones, and market developments.
What are small medical device companies worth researching?
Small medical device companies on the ASX and globally offer investors exposure to innovative technology at earlier stages of development, where the return potential is highest. Key assessment criteria include regulatory pathway clarity, addressable market size, manufacturing scalability, and management track record. StockWire X covers small medical device and equipment companies with ongoing news and analysis.
What drives the share price of medical equipment stocks?
Medical equipment stock prices are driven by regulatory approvals and product launches, earnings results relative to guidance, contract and tender wins, acquisition activity, and the capital expenditure cycle in hospital systems. Companies with high recurring consumable and service revenue show more stable share price behaviour than those dependent on lumpy capital equipment sales.
How do hospital capital expenditure cycles affect medical equipment company revenues?
Medical equipment companies selling high-value capital equipment are significantly affected by hospital capital expenditure cycles. During periods of constrained hospital budgets, capital equipment purchases are often deferred, creating revenue headwinds. When hospital finances improve or government funding initiatives stimulate investment, equipment demand accelerates. Investors track hospital sector financial health and government infrastructure spending programmes to anticipate demand conditions.
What is the installed base business model and why is it valued highly in medical equipment investing?
The installed base model involves selling capital equipment competitively to establish a large customer base, then generating recurring, high-margin revenue from consumables, reagents, service contracts, and software. Companies with large installed bases generate predictable recurring revenues that are less cyclically sensitive than capital equipment sales alone. Investors value recurring revenue streams at higher multiples because they are more predictable and have lower customer acquisition costs.
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time